Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Dianthus Therapeutics, Inc. has received a consensus rating of "Moderate Buy" from analysts, with ten out of eleven firms recommending a buy.
• The stock recently opened at $33.45 but has experienced a 4.5% decline, with a twelve-month high of $40.16 and a low of $13.36.
• In its latest earnings report, Dianthus reported a loss of ($0.88) per share, missing consensus estimates, and had a revenue of only $0.19 million, significantly below expectations.

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $60.8750.

A number of equities analysts recently commented on the stock. Truist Financial assumed coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 14th. They set a "buy" rating and a $56.00 price target for the company. Wedbush upped their target price on Dianthus Therapeutics from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Friday, September 12th. Robert W. Baird lifted their target price on Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an "outperform" rating in a report on Tuesday, September 9th. William Blair started coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, September 8th.

Dianthus Therapeutics Stock Down 4.5%

Dianthus Therapeutics stock opened at $33.45 on Thursday. The company has a market capitalization of $1.08 billion, a PE ratio of -10.29 and a beta of 1.58. The firm has a fifty day simple moving average of $31.98 and a two-hundred day simple moving average of $23.63. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $40.16.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. As a group, equities analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Ryan Savitz sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.15% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the 2nd quarter worth about $27,000. US Bancorp DE boosted its stake in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after buying an additional 1,510 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after buying an additional 3,758 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after acquiring an additional 3,317 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in shares of Dianthus Therapeutics during the second quarter valued at approximately $94,000. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.